LivaNova Announces OSPREY Clinical Study Meets Primary Safety …
4 days ago · LONDON -- (BUSINESS WIRE)--Nov. 11, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that it met the primary endpoints for its OSPREY randomized controlled trial (RCT), Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation. Together with its safety endpoints, the RCT ...
LivaNova Announces OSPREY Clinical Study Meets Primary Safety …
3 days ago · LivaNova Investor Relations and Media Contacts. +1 281-895-2382. Briana Gotlin. VP, Investor Relations. [email protected]. Deanna Wilke. VP, Corporate Communications. Corporate ...
LivaNova Announces OSPREY Clinical Study Meets Primary Safety …
4 days ago · Median oxygen desaturation index reduction of 63.3%. LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that it met the primary endpoints for its OSPREY ...
LivaNova announces OSPREY clinical study meets safety/efficacy ...
4 days ago · LivaNova “announced that it met the primary endpoints for its OSPREY randomized controlled trial, Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation. Together with its ...
LivaNova Announces OSPREY Clinical Study Meets Primary Safety …
3 days ago · LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that it met the primary endpoints for its OSPREY randomized controlled trial (RCT), Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation.Together with its safety endpoints, the RCT achieved statistical significance of its primary endpoint responder rates 1,2 between the treatment ...
LivaNova Announces a Positive Predictive Outcome of Trial …
Mar 20, 2024 · After the full cohort completes the seven-month follow-up visit and the results are compiled, LivaNova will submit OSPREY’s final clinical module to the FDA. “We are pleased to have achieved this positive milestone for the OSPREY study,” said Vladimir Makatsaria, Chief Executive Officer of LivaNova. “In accordance with the study ...
LivaNova Announces a Positive Predictive Outcome of Trial …
Mar 20, 2024 · OSPREY is a prospective, multi-center, randomized controlled open-label trial demonstrating the safety and effectiveness of the aura6000™ Hypoglossal Nerve Stimulator System versus a no ...
OSPREY Obstructive Sleep Apnea Trial Achieves Positive Predictive ...
Mar 26, 2024 · LivaNova announces a positive predictive outcome of trial success in its OSPREY clinical study for moderate to severe obstructive sleep apnea. LivaNova website. Published March 20, 2024.
LivaNova nerve stim for sleep apnea meets study endpoints
3 days ago · November 11, 2024 By Sean Whooley. LivaNova (Nasdaq:LIVN) today announced that its OSPREY trial of nerve stimulation for treating sleep apnea met its primary endpoints. OSPREY evaluates targeted ...
LivaNova plc (LIVN) Announces OSPREY Clinical Study Meets …
3 days ago · Once the six-month results analysis is completed, LivaNova will submit the OSPREY clinical data to the U.S. Food and Drug Administration (FDA) as part of its premarket approval submission for the ...
- Some results have been removed